Adenovir Pharma´s patent applications relating to its novel “antiviral compound” (APD-209) for treatment of the serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC), have been approved in several countries. Most recently it was granted in Russia by the Federal Service for Intellectual Property.
The company’s base patent, which relates to its technology platform, is already granted in several important markets such as EU, US, Japan, China, etc.
New medical treatment under development
EKC (epidemic keratoconjunctivitis)affects millions of people every year all over the world and can lead to sight impairment. Today there is no effective antiviral treatment for EKC. Adenovir Pharma develops a new and innovative drug against the serious and very contagious eye disease EKC. A double-blind randomized phase 2 study is in progress at several eye clinics in Sweden and Germany. Adenovir Pharma has previously demonstrated in a phase 1 study that this drug candidate, APD-209, is well tolerated. VINNOVA, the Swedish Governmental Agency for Innovation Systems, has granted Adenovir Pharma funding for the pharmaceutical development of a second generation drug, APD-514, against EKC.
For more information, please contact:
Björn Dellgren, CEO/project leader, Adenovir Pharma AB, firstname.lastname@example.org or
+46 (0)707 455 005.
About epidemic keratoconjunctivitis (EKC)
External ocular infections caused by adenoviruses are among the most common eye infections worldwide, affecting millions of people every year. EKC is a serious and very contagious eye infection caused by adenoviruses that can lead to sight impairment for a long time after the acute phase. Both the cornea and the conjunctiva are affected and the disease is very painful in the acute phase. EKC occurs all over the world but is most common in densely populated areas in Asia, where the disease is considered to be a major health problem. In Japan alone one million people are affected by eye infections caused by adenoviruses every year. The patients and persons in their closest environment must often be isolated during the acute phase. The patients are generally on sick leave. During epidemics in Asia it happens that schools and workplaces must be closed. The costs for society in the form of lost working days and production are consequently high. Between 20 and 50 percent of those affected suffer sight impairment that can persist for months and in some cases for several years. Sporadic outbreaks occur as epidemics in many regions. Currently there are no effective drugs against EKC and the persons affected thus get no treatment.
Adenovir Pharma AB is a project company within P.U.L.S. AB, a life science development company, based in Helsingborg, Sweden. Adenovir has a proprietary technology platform and is developing an antiviral drug for the treatment of a serious and very contagious eye infection, epidemic keratoconjunctivitis (EKC).The initial development was carried out in close collaboration with professors Göran Wadell and Niklas Arnberg at the virology laboratory at Umeå University, in Sweden, and researchers at the Department of Organic Chemistry at Lund University, in Sweden, professors Olov Sterner and Ulf Ellervik, together with PULS and a number of specialized drug development companies. Discoveries on which the development of the drug candidate APD-209 is based have been published in the prestigious journals Nature Medicine and Journal of Medicinal Chemistry. The importance of this discovery has furthermore been highlighted in the equally high-ranking journal Nature Reviews Drug Discovery. The drug candidate has proved to be well tolerated and safe in preclinical and clinical phase 1 studies and is now being tested clinically in a phase 2 study. The new second generation drug, APD-514, has been developed in collaboration with professors Niklas Arnberg and Mikael Elofsson at Umeå University and has been shown to have high potency, good pharmaceutical properties and to be well tolerated in pre-clinical studies. Read more at www.adenovir.com.
P.U.L.S. AB (partners for development investments in life sciences) is a unique life science development company. PULS invests in early projects and actively develops them in close collaboration with the innovators, all the way from idea to projects attractive to the industry. Since 2002 PULS has started ten project companies and exited three, one of which, LIDDS, is listed. PULS is headquartered in Helsingborg, Sweden. PULS’ current projects are: AcuCort, Adenovir Pharma, Glactone Pharma, Laccure, Oncorena and Trophea. Read more at www.pulsinvest.se.